MICHELLE ADAMS: Open Payments
NPI 1578586863 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$839 in 29 payments from 11 companies in 2025. Trend: 2023 $718 · 2024 $540 · 2025 $839
Food & beverage: $839
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 4 | $165 |
| Kowa Pharmaceuticals America, Inc. | 1 | $117 |
| ABBVIE INC. | 6 | $106 |
| AstraZeneca Pharmaceuticals LP | 1 | $101 |
| Merck Sharp & Dohme LLC | 1 | $98 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $58 |
| PFIZER INC. | 3 | $53 |
| Lilly USA, LLC | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 3 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $34 |
Products named: ZORYVE, Yeztugo, BREZTRI, CAPVAXIVE, VRAYLAR, CAPLYTA, MOUNJARO, UBRELVY.
Industry payments across KY — which companies pay providers there.
